NP102

About Nostopharma

Nostopharma is a preclinical-stage biotech leveraging drug repurposing to develop small molecule therapies for heterotopic ossification (HO) and other conditions. Its lead strategy involves using approved Hedgehog inhibitors to prevent abnormal bone growth following trauma, supported by positive mouse model data. The company maintains a balanced portfolio with programs in oncology and regenerative medicine, emphasizing clear biomarkers and partnership-ready paths for de-risked execution.

Therapeutic Areas